LADENBURG THALM/SH SH cut shares of Tocagen (NASDAQ:TOCA) from a buy rating to a neutral rating in a report released on Thursday morning, The Fly reports.

Other equities analysts have also issued research reports about the stock. Robert W. Baird lowered shares of Tocagen from an outperform rating to a neutral rating in a report on Thursday. Chardan Capital reaffirmed a buy rating and set a $10.00 target price on shares of Tocagen in a report on Wednesday, May 22nd. Citigroup assumed coverage on shares of Tocagen in a report on Thursday, May 30th. They set a buy rating on the stock. Leerink Swann set a $5.00 target price on shares of Tocagen and gave the company a hold rating in a report on Wednesday, May 22nd. Finally, Cantor Fitzgerald lowered shares of Tocagen from an overweight rating to a neutral rating in a report on Thursday. Nine analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Tocagen currently has a consensus rating of Hold and an average target price of $12.95.

Shares of Tocagen stock traded up $0.11 on Thursday, hitting $1.04. 2,658,665 shares of the company traded hands, compared to its average volume of 256,770. The firm’s 50-day simple moving average is $4.35 and its 200 day simple moving average is $7.28. The company has a current ratio of 4.21, a quick ratio of 4.21 and a debt-to-equity ratio of 0.86. The company has a market cap of $89.61 million, a P/E ratio of -0.43 and a beta of 4.07. Tocagen has a 12-month low of $0.73 and a 12-month high of $15.80.

Tocagen (NASDAQ:TOCA) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.72) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.76) by $0.04. The firm had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.50 million. Tocagen had a negative net margin of 300.42% and a negative return on equity of 115.81%. Analysts predict that Tocagen will post -2.67 earnings per share for the current year.

Hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Arbitrage SA grew its holdings in shares of Tocagen by 72,350.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 4,347 shares of the company’s stock valued at $47,000 after purchasing an additional 4,341 shares during the last quarter. Creative Planning bought a new position in shares of Tocagen during the 1st quarter valued at $117,000. Parametric Portfolio Associates LLC bought a new position in shares of Tocagen during the 2nd quarter valued at $75,000. Bank of America Corp DE grew its holdings in shares of Tocagen by 28.6% during the 4th quarter. Bank of America Corp DE now owns 14,584 shares of the company’s stock valued at $120,000 after purchasing an additional 3,240 shares during the last quarter. Finally, A.R.T. Advisors LLC bought a new stake in Tocagen in the 2nd quarter worth $114,000. 35.43% of the stock is currently owned by institutional investors.

Tocagen Company Profile

Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.

Read More: What is Liquidity?

The Fly

Analyst Recommendations for Tocagen (NASDAQ:TOCA)

Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.